DGCR6L

Across TCGA pan-cancer cohorts, DGCR6L Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DGCR6L data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher DGCR6L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DGCR6L expression acts as an unfavorable survival marker.

ESCA are the cancer types where DGCR6L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.089	0.522	.001	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

DGCR6L–ESCA (DFS)

Open the ESCA breakdown →